Dishman Carbogen Amcis (BSE:540701) - Share price, News & Analysis

540701 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

540701 Overview

Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide.

Rewards

Earnings are forecast to grow 123.67% per year

Risk Analysis

No risks detected for 540701 from our risk checks.

Dishman Carbogen Amcis Competitors

Divi's Laboratories

NSEI:DIVISLAB

₹1.3t

Syngene International

BSE:539268

₹217.6b

Suven Life Sciences

BSE:530239

₹26.0b

Dr. Reddy's Laboratories

BSE:500124

₹774.2b

Price History & Performance

Summary of all time highs, changes and price drops for Dishman Carbogen Amcis
Historical stock prices
Current Share Price	₹216.65
52 Week High	₹102.55
52 Week Low	₹259.50
Beta	1.61
1 Month Change	9.72%
3 Month Change	3.61%
1 Year Change	39.59%
3 Year Change	-7.18%
5 Year Change	n/a
Change since IPO	-38.32%

Shareholder Returns

	540701	IN Life Sciences	IN Market
7D	1.6%	-4.2%	-2.3%
1Y	39.6%	46.8%	62.5%

Return vs Industry: 540701 underperformed the Indian Life Sciences industry which returned 46.8% over the past year.

Return vs Market: 540701 underperformed the Indian Market which returned 62.5% over the past year.

Price Volatility

Is 540701's price volatile compared to industry and market?
540701 volatility
540701 Beta	1.61
Industry Beta	0.36
Market Beta	1

Stable Share Price: 540701 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 540701's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1983	929	Mark Griffiths	https://imdcal.com

Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, intermediates, phase transfer catalysts, quaternary ammonium compounds, phosphoranes, wittig reagents, vitamin D products, fine chemicals, hand and body wash, sanitisers, antiseptics, and various pharmaceutical and cosmetic-related products, as well as generic and highly potent active pharmaceutical ingredients.

Dishman Carbogen Amcis Fundamentals Summary

How do Dishman Carbogen Amcis's earnings and revenue compare to its market cap?
540701 fundamental statistics
Market Cap	₹33.97b
Earnings (TTM)	-₹1.28b
Revenue (TTM)	₹19.88b

1.7x

P/S Ratio

-26.6x

P/E Ratio

Is 540701 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
540701 income statement (TTM)
Revenue	₹19.88b
Cost of Revenue	₹5.41b
Gross Profit	₹14.47b
Expenses	₹15.75b
Earnings	-₹1.28b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Oct 28, 2021

Earnings per share (EPS)	-8.14
Gross Margin	72.78%
Net Profit Margin	-6.42%
Debt/Equity Ratio	27.9%

How did 540701 perform over the long term?

See historical performance and comparison

Valuation

Is Dishman Carbogen Amcis undervalued compared to its fair value and its price relative to the market?

0.6x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: 540701 (₹216.65) is trading above our estimate of fair value (₹9.81)

Significantly Below Fair Value: 540701 is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: 540701 is unprofitable, so we can't compare its PE Ratio to the Indian Life Sciences industry average.

PE vs Market: 540701 is unprofitable, so we can't compare its PE Ratio to the Indian market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 540701's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 540701 is good value based on its PB Ratio (0.6x) compared to the IN Life Sciences industry average (3.6x).

Future Growth

How is Dishman Carbogen Amcis forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

123.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 540701 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (6.7%).

Earnings vs Market: 540701 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 540701's is expected to become profitable in the next 3 years.

Revenue vs Market: 540701's revenue (13% per year) is forecast to grow faster than the Indian market (12.6% per year).

High Growth Revenue: 540701's revenue (13% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 540701's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Dishman Carbogen Amcis performed over the past 5 years?

-25.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 540701 is currently unprofitable.

Growing Profit Margin: 540701 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 540701 is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.

Accelerating Growth: Unable to compare 540701's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 540701 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (34.7%).

Return on Equity

High ROE: 540701 has a negative Return on Equity (-2.24%), as it is currently unprofitable.

Financial Health

How is Dishman Carbogen Amcis's financial position?

Financial Position Analysis

Short Term Liabilities: 540701's short term assets (₹16.6B) exceed its short term liabilities (₹12.5B).

Long Term Liabilities: 540701's short term assets (₹16.6B) exceed its long term liabilities (₹13.8B).

Debt to Equity History and Analysis

Debt Level: 540701's debt to equity ratio (27.9%) is considered satisfactory.

Reducing Debt: 540701's debt to equity ratio has increased from 20.3% to 27.9% over the past 5 years.

Debt Coverage: 540701's debt is well covered by operating cash flow (32.3%).

Interest Coverage: 540701's interest payments on its debt are well covered by EBIT (7.1x coverage).

Balance Sheet

Dividend

What is Dishman Carbogen Amcis's current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 540701's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 540701's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 540701's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 540701's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: 540701 is not paying a notable dividend for the Indian market.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 540701's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average board tenure

CEO

Mark Griffiths (57 yo)

no data

Tenure

Mr. Mark Christopher Griffiths serves as Global Chief Executive Officer at Dishman Pharmaceuticals and Chemicals Limited. Mr. Griffiths serves as Global Chief Executive Officer at Dishman Carbogen Amcis Li...

Board Members

Experienced Board: 540701's board of directors are considered experienced (4.6 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2021/10/27 12:04
End of Day Share Price	2021/10/27 00:00
Earnings	2021/06/30
Annual Earnings	2021/03/31

Market Cap

7D

1Y

Updated

Data